

06-10-2003



To the Honorable Commissioner of Patents

102468379

3 original documents or copy thereof.

1. Name of conveying party(ies):

Aventis Holdings, Inc.

FINANCE SECTION

5.12.03

☐

Individual(s)

☐

Association

☐

General Partnership

☐

Limited Partnership

☒

Corporation-State

☐☐

Other

Additional name(s) of conveying party(ies)

☐ Yes☒ No

3. Nature of conveyance:

☒

Assignment

☐

Merger

☐

Security Agreement

☐

Change of Name

☐

Other

Execution Date **January 15, 2002**

2. Name and address of receiving party(ies):

Name: **Novartis Consumer Health, Inc.**

Internal Address:

Street Address: **200 Kimball Drive**

City: **Parsippany** State: **NJ** Zip: **07054-0622**

☐

Individual(s) citizenship

☐

Association

☐

General Partnership

☐

Limited

☒

Corporation-State

Delaware

☐

Other

If assignee is not domiciled in the United States, a domestic representative designation is attached: ☐ Yes ☒ No

(Designations must be a separate document from assignment)

Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application number(s) or patent number(s):

A. Trademark Application No.(s)

B. Trademark Registration No. **1949046**

Additional numbers attached?

☐ Yes☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: **Mary F. Leheny**

Internal Address: **Patent and Trademark Department**

Street Address: **One Health Plaza**

Bldg 430

City: **East Hanover** State **NJ** Zip: **07936-1080**

6. Total number of applications and registrations involved:

1

7. Total fee (37 CFR 3.41)\$ **40.00**

☐

Enclosed

☒

Authorized to be charged to deposit account

8. Deposit account number:

50-0430

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature. To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Mary F. Leheny

Name of Person Signing

Mary F. Leheny

Signature

May 13, 2003

Date

Total number of pages including cover sheet, attachments, and document: **5**

**SECOND AMENDMENT TO INTELLECTUAL PROPERTY AGREEMENT
DATED DECEMBER 20, 1994 BETWEEN RORER PHARMACEUTICALS
PRODUCTS, INC. AND CIBA SELF-MEDICATION, INC.**

THIS AGREEMENT, effective January 15, 2002, is made and entered by and between Novartis Consumer Health, Inc., 200 Kimball Drive, Parsippany, New Jersey 07054-0622 (hereinafter referred to as "Novartis") and Aventis Holdings, Inc. (hereinafter referred to as "Aventis").

WITNESSETH:

WHEREAS Novartis and Aventis are successors-in-interest to a certain Intellectual Property Agreement between Rorer Pharmaceuticals Products, Inc. and Ciba Self-Medication Inc. dated as of December 30, 1994, and a certain Amendment to the Intellectual Property Agreement between Rorer Pharmaceuticals Products, Inc. and Ciba Self-Medication Inc. dated as of December 30, 1994, effective as of January 15, 2002, (collectively the "Intellectual Property Agreement");

WHEREAS Novartis and Aventis wish to amend the Intellectual Property Agreement;

NOW, THEREFORE, in consideration of the mutual promises, agreements and undertakings set forth in the Intellectual Property Agreement and Notice and hereinafter set forth, it is hereby agreed by and between the parties to amend the Intellectual Property Agreement as follows:

1. Exhibit B to the Intellectual Property Agreement shall include MAALOX, U.S. trademark Registration No. 1949046.
2. Except as expressly set forth herein, all terms and conditions of the Intellectual Property Agreement shall remain in full force and effect.


IN WITNESS WHEREOF the parties hereto have caused this Second Amendment to the Intellectual Property Agreement to be executed by their respective duly-authorized representatives.

NOVARTIS CONSUMER HEALTH, INC.



Name: Christopher G. FitzPatrick
Title: Sr. Vice President & General Counsel
Date: May 12, 2003

AVENTIS HOLDINGS INC.



Name: Joseph M. Palladino
Title: President
Date: April 10, 2003